Clinical Trials match your criteria
-
First-Line Treatment in Patients With Epidermal Growth Factor Receptor(EGFR) Mutation Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase III, Open-label, Randomized Study of Osimertinib With or Without Platinum Plus Pemetrexed Chemo, as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2)
-
A Phase III Trial in Metastatic Untreated Renal Cell Cancer
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]
-
Ph3 of MK6482 with Lenvatinib vs Cabozantinib for Advanced RCC
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti- PD-1/L1 Therapy
-
Radiation Therapy on the First Visit: Virtual Radiation Treatment Planning for Palliative Cases
Radiation Therapy on the First Visit: Virtual Radiation Treatment Planning for Palliative Cases
-
Ph3 of MK6482 with Lenvatinib vs Cabozantinib for Advanced RCC
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti- PD-1/L1 Therapy
-
Radiation Therapy on the First Visit: Virtual Radiation Treatment Planning for Palliative Cases
Radiation Therapy on the First Visit: Virtual Radiation Treatment Planning for Palliative Cases
-
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study
Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: Alchemist Chemo-IO
-
Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
-
Nivolumab or Placebo combined with Docetaxel
A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer
NAVIGATE YOUR HEALTH
Find a Cancer Physician
Find a Cancer Physician
Meet our doctors who specialize in the full range of cancer care. Our team of experts has experience in a variety of specialty areas. Together, we provide comprehensive evaluation, diagnosis and treatment options.
Learn More >
Patient Portal
Patient Portal
If you are a patient at Orlando Health Cancer Institute, our free online patient portal provides an easy and secure way to manage your health information. Reach us from any location at a time that’s convenient for you.
Learn More >
Virtual Visit
Virtual Visit
Need to talk with a doctor, but don’t want to leave your home? Try our virtual visit (telehealth) option to connect with a physician from your phone, tablet or computer.
Learn More >